News On Neos Therapeutics Inc. (NEOS) Now Under AYTU
News On Neos Therapeutics Inc. (NEOS) Now Under AYTU
Dow Jones · 03/22 21:08
Global Sodium Vapor Lamp Transformer Market 2020 Product Introduction, Recent Developments, Competitive Landscape and Dynamics by 2025
Mar 22, 2021 (CDN Newswire via Comtex) -- The latest report entitled Global Sodium Vapor Lamp Transformer Market Growth 2020-2025 is an in-depth analysis of... · 03/22 20:40
Aytu BioScience Announces Close of Merger with Neos Therapeutics
$100M revenue specialty pharmaceutical company on an accelerated path to profitability[1] Company name change to Aytu BioPharma, Inc. becomes effective today Former Neos Therapeutics board members Beth P. Hecht and Gerald McLaughlin have joined the Aytu Bi...
ACCESSWIRE · 03/22 10:00
The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 18)
Benzinga · 03/19 11:46
Why Did Aytu Biosciences Gap Up Today? Technical Levels To Watch
Aytu Biosciences Inc. (NASDAQ: AYTU) shares gapped up Thursday morning.
Benzinga · 03/18 21:34
Neos Therapeutics, Aytu BioScience leads healthcare gainers; Translate Bio, ContraFect among major losers
Gainers: Neos Therapeutics (NEOS) +17%,Aytu BioScience (AYTU) +14%, Vericel (VCEL) +14%, Brickell Biotech (BBI) +14%, Infinity Pharmaceuticals INFI +13%.Losers: Translate Bio TBIO -32%, ContraFect CFRX -13%, Lipocine (LPCN) -11%, Olema Pharmaceuticals (OLM...
Seekingalpha · 03/18 15:02
Thinking about buying stock in Neos Therapeutics, Oriental Culture, Sino-Global Shipping, Bank of America, or Can Fite Biopharma?
NEW YORK, March 18, 2021 /PRNewswire via COMTEX/ -- NEW YORK, March 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS,...
PR Newswire - PRF · 03/18 14:42
HEXO, CSIQ, LAZR and SIG among premarket gainers
BioHiTech Global (BHTG) +44% on receiving $2M in Digester orders.Upstart Holdings (UPST) +39% on Q4 results.Neos Therapeutics (NEOS) +30%.Seneca Biopharma (SNCA) +26%.Evolving Systems (EVOL) +24% on Q4 results.Can-Fite BioPharma (CANF) +17% on announcing n...
Seekingalpha · 03/18 12:29
Why Are Neos Therapeutics, Aytu BioScience Stocks Soaring Today?
Benzinga · 03/18 11:22
3 Penny Stocks To Watch Today After Big News This Week
Mar 16, 2021 (Penny Stocks via COMTEX) -- Penny Stock News Triggers Momentum In These Cheap Stocks When it comes to penny stocks, there are plenty of...
Penny Stocks · 03/16 16:11
Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors
Patrick Heron to leave the Board
GlobeNewswire · 03/16 11:30
BRIEF-Glass Lewis Recommends Neos Therapeutics Stockholders Vote “For” The Pending Merger With Aytu Bioscience · 03/12 14:28
Global Attention deficit Hyperactivity Disorder (ADHD) Drugs Market Size and Share 2021 Industry Evolution to 2023 by Growth Insight, Business Analysis, Key Development, Trends and Forecast
Mar 12, 2021 (The Expresswire) -- Global "Attention deficit Hyperactivity Disorder (ADHD) Drugs Market" (2021) thoroughly scrutinizes the effects of a wide...
The Express Wire · 03/12 08:21
Neos Therapeutics Board Recommend Stockholders Vote "FOR" the Transaction >NEOS
Neos Therapeutics Board Recommend Stockholders Vote "FOR" the Transaction >NEOS
Dow Jones · 03/10 21:21
4 Penny Stocks Nearing 2021 Highs But Are They A Buy Right Now?
Feb 24, 2021 (Penny Stocks via COMTEX) -- Are These On Your List Of Penny Stocks To Buy Or Avoid? This year is off to a roaring start, and penny stocks are...
Penny Stocks · 02/24 21:07
Hercules Capital Reports Fourth Quarter and Full-Year 2020 Financial Results
--Q4 2020 Net Investment Income Provides 116% Coverage of Base Distribution Payout
BusinessWire · 02/23 21:10
ADHD Therapeutics Market: 2021 Global Industry Size, Share, Growth Opportunities, Analysis, Developments Trends, Forecast To 2025
Heraldkeepers · 02/16 10:40
Aytu BioScience Announces Record Fiscal Q2 2021 Net Revenue of $15.1 Million, an Increase of 377% Year-Over-Year
February 11, 2021 (ACCESSWIRE via COMTEX) -- Announced definitive merger agreement with Neos Therapeutics, creating a combined $100 million revenue specialty...
ACCESSWIRE · 02/11 21:01
Webull provides a variety of real-time NEOS stock news. You can receive the latest news about Neos through multiple platforms. This information may help you make smarter investment decisions.
About NEOS
Neos Therapeutics, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and manufacturing central nervous system (CNS) focused products. The Company markets Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate) and Adzenys-ER (amphetamine), all for the treatment of attention deficit hyperactivity disorder (ADHD). The Company manufactures and markets a generic Tussionex (hydrocodone and chlorpheniramine) (generic Tussionex), for the treatment of cough and upper respiratory symptoms of a cold. It is also developing N-desethyloxybutynin (NT0502), for the treatment of sialorrhea in patients with neurological conditions. NT0502 is a selective anticholinergic agent that is developing an oral, treatment to reduce chronic sialorrhea in patients with neurological conditions associated with salivation and drooling.